Background. There is strong concern about the costs associated with adding tumor-treating fields (TTF) therapy to standard firstling treatment for glioblastoma (GBM). Hence, we aimed to determine the cost-effectiveness of TTF therapy for the treatment of newly diagnosed patients with GBM. Methods. We developed a 3-health-state Markov model. The perspective was that of the French Health Insurance, and the horizon was lifetime. We calculated the transition probabilities from the survival parameters reported in the EF-14 trial. The main outcome measure was incremental effectiveness expressed as life-years gained (LYG). Input costs were derived from the literature. We calculated the incremental cost-effectiveness ratio (ICER) expressed as co...
<div><h3>Background</h3><p>The aim of this research was to evaluate the economic outcomes of radioth...
AIM: To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant ...
Effectiveness and costs of care and treatment of recurrent malignant gliomas are largely unknown. In...
cited By 18International audienceBackground There is strong concern about the costs associated with ...
cited By 0Purpose: A first cost-effectiveness analysis has raised a strong concern regarding the cos...
BACKGROUND: The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomi...
BACKGROUND. The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomi...
Background: Tumor treating fields (TTF) was first approved for treatment of glioblastoma. Recently, ...
What is known and objective Therapeutic options for the management of glioblastoma (GBM) have great...
cited By 5International audienceWhat is known and objective: Therapeutic options for the management ...
BACKGROUND: Adding temozolomide (TMZ) to standard radiotherapy as a first-line therapy for glioma ma...
BACKGROUND: High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse i...
Recurrent glioblastoma (GBM) is a disease with poor prognosis. Although several therapeutic approach...
BACKGROUND: The aim of this research was to evaluate the economic outcomes of radiotherapy (RT), tem...
What is new and objectives Trends in the care of glioblastoma in actual practice settings are poorl...
<div><h3>Background</h3><p>The aim of this research was to evaluate the economic outcomes of radioth...
AIM: To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant ...
Effectiveness and costs of care and treatment of recurrent malignant gliomas are largely unknown. In...
cited By 18International audienceBackground There is strong concern about the costs associated with ...
cited By 0Purpose: A first cost-effectiveness analysis has raised a strong concern regarding the cos...
BACKGROUND: The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomi...
BACKGROUND. The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomi...
Background: Tumor treating fields (TTF) was first approved for treatment of glioblastoma. Recently, ...
What is known and objective Therapeutic options for the management of glioblastoma (GBM) have great...
cited By 5International audienceWhat is known and objective: Therapeutic options for the management ...
BACKGROUND: Adding temozolomide (TMZ) to standard radiotherapy as a first-line therapy for glioma ma...
BACKGROUND: High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse i...
Recurrent glioblastoma (GBM) is a disease with poor prognosis. Although several therapeutic approach...
BACKGROUND: The aim of this research was to evaluate the economic outcomes of radiotherapy (RT), tem...
What is new and objectives Trends in the care of glioblastoma in actual practice settings are poorl...
<div><h3>Background</h3><p>The aim of this research was to evaluate the economic outcomes of radioth...
AIM: To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant ...
Effectiveness and costs of care and treatment of recurrent malignant gliomas are largely unknown. In...